Related Experiment Video

Updated: Jul 9, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.2K

Corrigendum to "International expert consensus on the clinical integration of circulating tumor cells in solid

Eleonora Nicolò1, Carolina Reduzzi1, Jean-Yves Pierga2

  • 1Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.

European Journal of Cancer (Oxford, England : 1990)
|December 11, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

8.9K
Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

4.6K

Related Experiment Videos

Last Updated: Jul 9, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.2K
Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

8.9K
Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

4.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.

Current opinion in oncology·2026

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival.

Breast cancer research and treatment·2026

Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB).

The journal of liquid biopsy·2026

Inflammatory breast cancer: Improving research and care through the integration of preclinical evidence and technological advances.

Critical reviews in oncology/hematology·2026

Improved Surfactant-Assisted One-Pot Sample Preparation for Robust Convenient Single-Cell Proteomics.

Journal of proteome research·2026

Bioinformatics of Shallow Whole Genome Sequencing Data of Circulating Tumor Cells to Inform Cancer Diagnosis and Treatment.

Methods in molecular biology (Clifton, N.J.)·2026

Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort.

European journal of cancer (Oxford, England : 1990)·2026

Timing of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation.

European journal of cancer (Oxford, England : 1990)·2026

Liquid biopsy tumour fraction, total tumour volume, and automated whole-body CT body composition for survival stratification in metastatic cancer: A temporally validated pan-cancer cohort study.

European journal of cancer (Oxford, England : 1990)·2026

Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?

European journal of cancer (Oxford, England : 1990)·2026

The UK's radiotherapy workforce shortage: Reforming regulation to address the gap.

European journal of cancer (Oxford, England : 1990)·2026

A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us